logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

NanoViricides, Inc.

NNVC

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, andā€¦ read more

Healthcare

Biotechnology

20 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.84

Price

-3.16%

-$0.06

$1.90

Previous Close

$1.85

Open

Premium

52w Discount
Market Cap

$32.073m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$9.727m

-17.3%

1y CAGR

-6.6%

3y CAGR

-2.9%

5y CAGR
EPS

-$0.71

-1.4%

1y CAGR

-0.6%

3y CAGR

+3.0%

5y CAGR
Book Value

$8.833m

$10.032m

Assets

$1.199m

Liabilities

-

Debt
Debt to Assets

0.0%

-

Debt to EBITDA
Free Cash Flow

-$8.403m

-29.8%

1y CAGR

-11.6%

3y CAGR

-2.0%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.